

Lihua Qiu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8968768/publications.pdf>

Version: 2024-02-01

28
papers

890
citations

516710

16
h-index

552781

26
g-index

30
all docs

30
docs citations

30
times ranked

1434
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiology and analysis of potential risk factors of high-risk human papillomavirus (HPV) in Shanghai China: A cross-sectional one-year study in non-vaccinated women. <i>Journal of Medical Virology</i> , 2022, 94, 761-770.	5.0	9
2	Chinese expert consensus on the clinical applications of aminolevulinic acid-based photodynamic therapy in female lower genital tract diseases (2022). <i>Photodiagnosis and Photodynamic Therapy</i> , 2022, 39, 102993.	2.6	15
3	Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer. <i>British Journal of Cancer</i> , 2021, 124, 414-424.	6.4	38
4	The effect of local photodynamic therapy with 5-aminolevulinic acid for the treatment of cervical low-grade squamous intraepithelial lesions with high-risk HPV infection: A retrospective study. <i>Photodiagnosis and Photodynamic Therapy</i> , 2021, 33, 102172.	2.6	19
5	Effectiveness of photodynamic therapy with 5-aminolevulinic acid on HPV clearance in women without cervical lesions. <i>Photodiagnosis and Photodynamic Therapy</i> , 2021, 34, 102293.	2.6	28
6	The effect of 5-Aminolaevulinic Acid Photodynamic Therapy versus CO ₂ laser in the Treatment of Cervical Low-grade Squamous Intraepithelial Lesions with High-Risk HPV Infection: A non-randomized, controlled pilot study. <i>Photodiagnosis and Photodynamic Therapy</i> , 2021, 36, 102548.	2.6	12
7	Clinical evaluation of a real-time optoelectronic device in cervical cancer screening. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 266, 182-186.	1.1	5
8	Effectiveness of photodynamic therapy in women of reproductive age with cervical high-grade squamous intraepithelial lesions (HSIL/CIN2). <i>Photodiagnosis and Photodynamic Therapy</i> , 2021, 36, 102517.	2.6	17
9	Clinical Evaluation of DNA Ploidy for the Triage of HPV-Positive Chinese Women During Cervical Cancer Screening. <i>Cancer Prevention Research</i> , 2021, 14, 355-362.	1.5	1
10	Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort. <i>BMC Infectious Diseases</i> , 2020, 20, 629.	2.9	73
11	Evaluation of p16/Ki-67 Dual-Stained Cytology in Triaging HPV-Positive Women during Cervical Cancer Screening. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1246-1252.	2.5	9
12	Genomic amplification of HPV, hTERT and cMYC in liquid-based cytological specimens for screening of cervical intraepithelial neoplasia and cancer. <i>Oncology Letters</i> , 2019, 17, 2099-2106.	1.8	10
13	Association between the vaginal microbiome and high-risk human papillomavirus infection in pregnant Chinese women. <i>BMC Infectious Diseases</i> , 2019, 19, 677.	2.9	49
14	Incidence of cervical high-grade squamous intraepithelial lesions and squamous cell carcinoma in women with high-risk human papillomavirus and normal cervical cytology: A retrospective analysis of 1858 cases stratified by age and human papillomavirus genotype. <i>Cytopathology</i> , 2019, 30, 419-425.	0.7	9
15	Erlotinib overcomes paclitaxel-resistant cancer stem cells by blocking the EGFR-CREB/GR ¹ -IL-6 axis in MUC1-positive cervical cancer. <i>Oncogenesis</i> , 2019, 8, 70.	4.9	33
16	TWEAK-stimulated macrophages inhibit metastasis of epithelial ovarian cancer via exosomal shuttling of microRNA. <i>Cancer Letters</i> , 2017, 393, 60-67.	7.2	77
17	Sphingosine kinase 1/sphingosine-1-phosphate (S1P)/S1P receptor axis is involved in ovarian cancer angiogenesis. <i>Oncotarget</i> , 2017, 8, 74947-74961.	1.8	43
18	Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1807-1816.	2.5	44

#	ARTICLE	IF	CITATIONS
19	Female third party lymphocytes are effective for immunotherapy of patients with unexplained primary recurrent spontaneous abortion: A retrospective analysis of outcomes. <i>European Journal of Contraception and Reproductive Health Care</i> , 2015, 20, 428-437.	1.5	5
20	MicroRNA-7 Inhibits Tumor Metastasis and Reverses Epithelial-Mesenchymal Transition through AKT/ERK1/2 Inactivation by Targeting EGFR in Epithelial Ovarian Cancer. <i>PLoS ONE</i> , 2014, 9, e96718.	2.5	84
21	Specific cell targeting with APRPG conjugated PEG-PLGA nanoparticles for treating ovarian cancer. <i>Biomaterials</i> , 2014, 35, 983-992.	11.4	49
22	Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells. <i>Biomaterials</i> , 2014, 35, 4297-4309.	11.4	101
23	Toxicity and therapy of cisplatin-loaded EGF modified mPEG-PLGA-PLL nanoparticles for SKOV3 cancer in mice. <i>Biomaterials</i> , 2013, 34, 4068-4077.	11.4	54
24	Paclitaxel and Ceramide synergistically induce cell death with transient activation of EGFR and ERK pathway in pancreatic cancer cells. <i>FASEB Journal</i> , 2006, 20, A694.	0.5	0
25	Crosstalk between EGFR and TrkB enhances ovarian cancer cell migration and proliferation. <i>International Journal of Oncology</i> , 2006, 29, 1003-11.	3.3	34
26	Paclitaxel and ceramide synergistically induce cell death with transient activation of EGFR and ERK pathway in pancreatic cancer cells. <i>Oncology Reports</i> , 2006, 16, 907-13.	2.6	33
27	Transient activation of EGFR/AKT cell survival pathway and expression of survivin contribute to reduced sensitivity of human melanoma cells to betulinic acid. <i>International Journal of Oncology</i> , 2005, 27, 823-30.	3.3	22
28	Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death. <i>International Journal of Oncology</i> , 2005, 27, 1441-8.	3.3	17